These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 19930153

  • 21. Genetic and clinical characteristics including occurrence of testicular adrenal rest tumors in Slovak and Slovenian patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Saho R, Dolzan V, Zerjav Tansek M, Pastorakova A, Petrovic R, Knapkova M, Trebusak Podkrajsek K, Suput Omladic J, Bertok S, Avbelj Stefanija M, Kotnik P, Battelino T, Pribilincova Z, Groselj U.
    Front Endocrinol (Lausanne); 2023; 14():1134133. PubMed ID: 37008950
    [Abstract] [Full Text] [Related]

  • 22. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
    Bonfig W, Schwarz HP.
    Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
    [Abstract] [Full Text] [Related]

  • 23. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls.
    Varness TS, Allen DB, Hoffman GL.
    J Pediatr; 2005 Oct; 147(4):493-8. PubMed ID: 16227036
    [Abstract] [Full Text] [Related]

  • 24. [Measurement of 17 OH progesterone in blood in Chilean newborns: antecedents for implementing a grogram for the neonatal detection of congenital adrenal hyperplasia].
    Cattani A, Reyes ML, Azócar M, Soto J, Romeo E, Valdivia L, Poggi H, Foradori A.
    Rev Med Chil; 2000 Oct; 128(10):1113-8. PubMed ID: 11349510
    [Abstract] [Full Text] [Related]

  • 25. Clinical and molecular profile of newborns with confirmed or suspicious congenital adrenal hyperplasia detected after a public screening program implementation.
    Kopacek C, Prado MJ, da Silva CMD, de Castro SM, Beltrão LA, Vargas PR, Grandi T, Rossetti MLR, Spritzer PM.
    J Pediatr (Rio J); 2019 Oct; 95(3):282-290. PubMed ID: 29715434
    [Abstract] [Full Text] [Related]

  • 26. Heterozygosis for CYP21A2 mutation considered as 21-hydroxylase deficiency in neonatal screening.
    Soardi FC, Lemos-Marini SH, Coeli FB, Maturana VG, Silva MD, Bernardi RD, Justo GZ, de-Mello MP.
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1388-92. PubMed ID: 19169499
    [Abstract] [Full Text] [Related]

  • 27. Non-classical congenital adrenal hyperplasia.
    Dacou-Voutetakis C, Dracopoulou M.
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():195-7. PubMed ID: 16641859
    [Abstract] [Full Text] [Related]

  • 28. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006.
    Dumic K, Krnic N, Skrabic V, Stipancic G, Cvijovic K, Kusec V, Stingl K.
    Horm Res; 2009 Jan; 72(4):247-51. PubMed ID: 19786796
    [Abstract] [Full Text] [Related]

  • 29. Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia.
    Silva RS, Carvalho B, Pedro J, Castro-Correia C, Carvalho D, Carvalho F, Fontoura M.
    Arch Endocrinol Metab; 2022 Apr 28; 66(2):168-175. PubMed ID: 35289513
    [Abstract] [Full Text] [Related]

  • 30. Serum 21-Deoxycortisol, 17-Hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency.
    Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto LM, Verreschi IT, Kater CE.
    J Clin Endocrinol Metab; 2006 Jun 28; 91(6):2179-84. PubMed ID: 16551734
    [Abstract] [Full Text] [Related]

  • 31. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden.
    Thil'en A, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A.
    Pediatrics; 1998 Apr 28; 101(4):E11. PubMed ID: 9521977
    [Abstract] [Full Text] [Related]

  • 32. CYP21A2 genotypes do not predict the severity of hyperandrogenic manifestations in the nonclassical form of congenital adrenal hyperplasia.
    Moura-Massari VO, Bugano DD, Marcondes JA, Gomes LG, Mendonca BB, Bachega TA.
    Horm Metab Res; 2013 Apr 28; 45(4):301-7. PubMed ID: 23322511
    [Abstract] [Full Text] [Related]

  • 33. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
    Kopacek C, de Castro SM, Prado MJ, da Silva CM, Beltrão LA, Spritzer PM.
    BMC Pediatr; 2017 Jan 17; 17(1):22. PubMed ID: 28095810
    [Abstract] [Full Text] [Related]

  • 34. Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points.
    Eshragh N, Doan LV, Connelly KJ, Denniston S, Willis S, LaFranchi SH.
    Horm Res Paediatr; 2020 Jan 17; 93(2):128-136. PubMed ID: 32659761
    [Abstract] [Full Text] [Related]

  • 35. Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
    Miller WL.
    Horm Res Paediatr; 2019 Jan 17; 91(6):416-420. PubMed ID: 31450227
    [Abstract] [Full Text] [Related]

  • 36. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
    Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A.
    J Pediatr; 1997 Jan 17; 130(1):128-33. PubMed ID: 9003862
    [Abstract] [Full Text] [Related]

  • 37. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.
    Therrell BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S.
    Pediatrics; 1998 Apr 17; 101(4 Pt 1):583-90. PubMed ID: 9521938
    [Abstract] [Full Text] [Related]

  • 38. Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia.
    Votava F, Török D, Kovács J, Möslinger D, Baumgartner-Parzer SM, Sólyom J, Pribilincová Z, Battelino T, Lebl J, Frisch H, Waldhauser F, Middle European Society for Paediatric Endocrinology -- Congenital Adrenal Hyperplasia (MESPE-CAH) Study Group.
    Eur J Endocrinol; 2005 Jun 17; 152(6):869-74. PubMed ID: 15941926
    [Abstract] [Full Text] [Related]

  • 39. Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia.
    Nascimento ML, Cristiano AN, Campos Td, Ohira M, Cechinel E, Simoni G, Lee Jv, Linhares RM, Silva PC.
    Arq Bras Endocrinol Metabol; 2014 Oct 17; 58(7):765-71. PubMed ID: 25372587
    [Abstract] [Full Text] [Related]

  • 40. Steroid Screening Tools Differentiating Nonclassical Congenital Adrenal Hyperplasia and Polycystic Ovary Syndrome.
    Maffazioli GDN, Bachega TASS, Hayashida SAY, Gomes LG, Valassi HPL, Marcondes JAM, Mendonca BB, Baracat EC, Maciel GAR.
    J Clin Endocrinol Metab; 2020 Aug 01; 105(8):. PubMed ID: 32530459
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.